Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationis. Nadège Cordel , Jasmine Flament , Fabienne Jouen , Vannina Seta , Emmanuelle Tancrède-Bohin , Catherine Picard Dahan , Maria-Polina Konstantinou , Olivier Dereure , Gaëlle Quéreux , Catherine Prost , Christophe Bedane , Sébastien Debarbieux , Jean-Philippe Lacour , Anne Dompmartin , Ewa Wierzbicka-Hainaut , Isabelle Bourgault Villada , Saskia Ingen Housz Oro , Pierre Vabres , Marie-Aleth Richard , Emmanuel Delaporte , Anne Pham-Ledard , Marie-Thérèse Leccia , Noémie Litrowski , Catherine Michel , Brigitte Lagrange , Michel D'Incan , Claire Abasq , Sophie Duvert-Lehembre , Alain Dupuy , Isabelle Alcaraz , Anne-Laure Breton-Guitarian , Florian Lombart , Eric Estève , Laurent Machet , Pascal Del Giudice , Marion Fenot , Thibaut Belmondo , Florence Morin , Olivia Guérin , Jacques Benichou , Benoît Tressières , Pascal Joly Journal of the European Academy of Dermatology and Venereology : JEADV（2023）
摘要
These findings suggest that anti-BP180 antibody ELISA value in combination with clinical markers is helpful in managing the risk of APO, in particular IUGR, in patients with PG.
更多 查看译文
关键词
adverse pregnancy outcomes, antibody
AI 理解论文
溯源树
样例
